Homocysteine and coronary heart disease: How great is the hazard?

JAMA

Volumn 288, Issue 16, 2002, Pages 2042-2043

  Wilson, Peter W F ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; FOLIC ACID ANTAGONIST; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; ISONIAZID; LOW DENSITY LIPOPROTEIN; METHOTREXATE; PYRIDOXINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIABETES MELLITUS; DIET SUPPLEMENTATION; EDITORIAL; FOLIC ACID BLOOD LEVEL; GENETIC RISK; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; VITAMIN SUPPLEMENTATION;

EID: 0037164051     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.16.2042     Document Type: Editorial

References (16)

1. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
2. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, and the MTHFR Studies Collaboration Group, MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023-2031.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
4. Petitti DB. Information Retrieval: Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York, NY: Oxford; 1994:43-69.
5. Ervin RB, Wright JD, Kennedy-Stephenson J. Use of dietary supplements in the United States, 1988-94. Vital Health Stat 11. 1999;244:1-14.
6. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
7. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
8. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
9. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health. 1998;88:15-19.
10. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. N Engl J Med. 1999;341:1485-1490.
11. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. JAMA. 1994;272: 1666-1671.
12. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999;99:178-182.
13. Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Ann Intern Med. 2001;135:133-137.
14. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593-1600.
15. 6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA. 2002;288:973-979.
16. Shemin D, Bostom AG, Selhub J. Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis. 2001;38(4 suppl 1):S91-S94.